BlackRock Group’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$36.3M Buy
302,724
+18,356
+6% +$2.03M 0.02% 662
2016
Q3
$31.9M Buy
284,368
+4,284
+2% +$493K 0.02% 687
2016
Q2
$34.7M Sell
280,084
-876
-0.3% -$106K 0.02% 658
2016
Q1
$31.6M Buy
280,960
+14,434
+5% +$1.5M 0.02% 690
2015
Q4
$29M Buy
266,526
+3,167
+1% +$363K 0.02% 701
2015
Q3
$26.3M Sell
263,359
-2,601
-1% -$283K 0.02% 710
2015
Q2
$30.3M Sell
265,960
-4,390
-2% -$532K 0.02% 712
2015
Q1
$28.2M Sell
270,350
-7,354
-3% -$783K 0.02% 728
2014
Q4
$33.4M Sell
277,704
-276
-0.1% -$36.3K 0.02% 688
2014
Q3
$40.7M Buy
277,980
+3,803
+1% +$587K 0.02% 623
2014
Q2
$45.8M Buy
274,177
+13,476
+5% +$2.4M 0.03% 591
2014
Q1
$51.7M Buy
260,701
+99,771
+62% +$18.8M 0.03% 550
2013
Q4
$30.7M Sell
160,930
-3,567
-2% -$664K 0.02% 658
2013
Q3
$27.8M Buy
164,497
+16,584
+11% +$2.57M 0.02% 685
2013
Q2
$22.4M Buy
+147,913
New +$21M 0.02% 694

Other funds holding CLB

BlackRock Group's CLB Position: Q4 2016 in Review

BlackRock Group increased its Core Laboratories (CLB) stake by 6.5% in Q4 2016, buying an estimated $2.03M and bringing the position to 302,724 shares worth $36.3M. The position accounts for 0.02% of the portfolio, ranked #662.

BlackRock Group first reported a position in CLB in Q2 2013 and has held it in 15 quarters since. The position peaked at $51.7M in Q1 2014. 372 funds tracked by Wall St. Rank hold CLB as of Q4 2016.

  • BlackRock Group held 302,724 shares of Core Laboratories worth $36.3M as of Q4 2016.
  • BlackRock Group bought 18,356 Core Laboratories shares in Q4 2016, an estimated $2.03M.
  • Core Laboratories made up 0.02% of BlackRock Group's portfolio in Q4 2016, its #662 holding.
  • BlackRock Group first reported a position in Core Laboratories in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Core Laboratories position peaked at $51.7M in Q1 2014.
  • 372 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.